Maxwellia Revenue and Competitors

Maxwellia is a pioneering British start-up pharma company building a pipeline of consumer healthcare brands that will help people look after themselves. We do this by converting prescription only medicines to versions that people can buy in a pharmacy. This process is known as switching (previous well-known examples of switches are Nurofen, Canesten and Viagra Connect). Switching is a rigorous regulatory process facilitating the safe supply of medicines under the supervision of a pharmacist. We are the world's only company with the commercial, medical, and scientific, innovation and regulatory acumen, switch expertise and dynamism, dedicated to bringing prescription medicines to life as brands that can be bought from the local pharmacy. In the UK £2bn is spent every year on 18 million GP consultations for conditions that people can manage for themselves. That's a lot of time that hard-pressed doctors could be spending on more serious conditions. Pharmacists are highly trained healthcare professionals and their expertise is extensive but currently the products they can sell to their customers are limited to traditional categories such as coughs, colds, pain, skin and digestive remedies, this limits their ability to play a bigger role, within primary care, and help ease the burden on doctors and the NHS. Our ambition is to widen access to a range of medicines and broaden the role of pharmacist so that people can access the advice and medicines they need to manage their health without the need for a GP appointment and prescription, thereby reducing the load on an over-stretched NHS. We're working across a wide range of therapy areas building our pipeline to widen access to a range of widely used and effective medicines delivering breakthrough products into the hands of the people that need them by making them convenient and easy to access in their local pharmacy Innovation is our everyday, helping people get their lives back is our mantra.